Indian drug maker Cipla Ltd has named chief operating officer (COO) Achin Gupta its next chief executive officer and managing director, succeeding Umang Vohra.
In a regulatory filing, the generics drug manufacturer said that Vohra has decided not to seek re-appointment upon completion of his current term on March 31, 2026.
Gupta will assume his new role, effective April 1, 2026, for a five-year term, pending shareholder approval.
The company stated that this "planned transition" aligns with the succession process developed by the board.
Gupta joined the company in 2021 and became COO in February 2025.
He currently oversees Cipla’s commercial markets, active pharmaceutical ingredient, manufacturing, and supply chain operations.
Gupta holds an MTech in Biochemical Engineering and Biotechnology from IIT Delhi and an MBA from IIM Ahmedabad.
Vohra had joined Cipla in 2015 as Global Chief Financial & Strategy Officer and thereafter served as Cipla’s MD & CEO since 2016.
Speaking on the announcement, Cipla chairman Dr Y K Hamied said, “I thank Umang for his stewardship over the last ten years, his outstanding contributions and dedication to Cipla’s purpose of Caring for Life and combining business with a humanitarian approach. We wish Umang continued success in his future career. We are pleased to welcome Achin Gupta as he steps into this role, and I am confident he will lead Cipla to its next phase of progress and growth.
Gupta said, “It is an honour to be entrusted with the responsibility of leading Cipla as its next MD & CEO."
